{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:15:25Z","timestamp":1791422125743,"version":"4.3.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB\/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and respond to treatments used for MM patients. Our system largely recapitulates human mesothelioma, and we advocate its use for the study of MM development and treatment.<\/jats:p>","DOI":"10.1038\/srep22850","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T10:43:54Z","timestamp":1457606634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells"],"prefix":"10.1038","volume":"6","author":[{"given":"Rosanna","family":"Mezzapelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltjona","family":"Rrapaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ceriotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco De","family":"Marchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Preti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello E.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Perani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Valtorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Moresco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Pecciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Frenquelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Recordati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Scanziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Berns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Frapolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Boldorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco E.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo P.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"BFsrep22850_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone, M. et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 227, 44\u201358 (2012).","journal-title":"J Cell Physiol."},{"key":"BFsrep22850_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone, M. et al. BAP1 and cancer. Nat Rev Cancer 13, 153\u2013159 (2013).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep22850_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","volume":"137","author":"AN Husain","year":"2013","unstructured":"Husain, A. N. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 137, 647\u2013667 (2013).","journal-title":"Arch Pathol Lab Med."},{"key":"BFsrep22850_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.ajpath.2013.12.008","volume":"184","author":"AH Rose","year":"2014","unstructured":"Rose, A. H. et al. Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. Am J Pathol. 184, 1041\u20131049 (2014).","journal-title":"Am J Pathol."},{"key":"BFsrep22850_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.humpath.2015.02.006","volume":"46","author":"B Davidson","year":"2015","unstructured":"Davidson, B. Prognostic factors in malignant pleural mesothelioma. Hum Pathol. 46, 789\u2013804 (2015).","journal-title":"Hum Pathol."},{"key":"BFsrep22850_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncponc1039","volume":"5","author":"DA Fennell","year":"2008","unstructured":"Fennell, D. A., Gaudino, G., O\u2019Byrne, K. J., Mutti, L. & van Meerbeeck, J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 5, 136\u2013147 (2008).","journal-title":"Nat Clin Pract Oncol."},{"key":"BFsrep22850_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone, M. & Yang, H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 18, 598\u2013604 (2012).","journal-title":"Clin Cancer Res."},{"key":"BFsrep22850_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","volume":"41","author":"V Panou","year":"2015","unstructured":"Panou, V. et al. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 41, 486\u2013495 (2015).","journal-title":"Cancer Treat Rev."},{"key":"BFsrep22850_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/TCRM.S1603","volume":"4","author":"R Goudar","year":"2008","unstructured":"Goudar, R. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag. 4, 205\u2013211 (2008).","journal-title":"Ther Clin Risk Manag."},{"key":"BFsrep22850_CR10","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","volume":"72","author":"S Jube","year":"2012","unstructured":"Jube, S. et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290\u20133301 (2012).","journal-title":"Cancer Res."},{"key":"BFsrep22850_CR11","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang, H. et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107, 12611\u201312616 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep22850_CR12","first-page":"422","volume":"18","author":"E V\u00e9n\u00e9reau","year":"2015","unstructured":"V\u00e9n\u00e9reau, E., Ceriotti, C. & Bianchi, M. E. DAMPs from Cell Death to New Life. Front Immunol. 18, 422 (2015).","journal-title":"Front Immunol."},{"key":"BFsrep22850_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860\u2013875 (2012).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep22850_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. & Robinson, B. W. Establishment of a murine model of malignant mesothelioma. Int J Cancer 52, 881\u2013886 (1992).","journal-title":"Int J Cancer"},{"key":"BFsrep22850_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01519898","volume":"40","author":"H Bielefeldt-Ohmann","year":"1995","unstructured":"Bielefeldt-Ohmann, H. et al. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 40, 241\u2013250 (1995).","journal-title":"Cancer Immunol Immunother."},{"key":"BFsrep22850_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","volume":"8","author":"MC Crisanti","year":"2009","unstructured":"Crisanti, M. C. et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 8, 2221\u20132231 (2009).","journal-title":"Mol Cancer Ther."},{"key":"BFsrep22850_CR17","first-page":"2648","volume":"19","author":"G Darrasse-J\u00e8ze","year":"2009","unstructured":"Darrasse-J\u00e8ze, G. et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest. 19, 2648\u20132662 (2009).","journal-title":"J Clin Invest."},{"key":"BFsrep22850_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/cgt.2010.21","volume":"17","author":"AS Bergot","year":"2010","unstructured":"Bergot, A. S. et al. Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells. Cancer Gene Ther. 17, 645\u2013654 (2010).","journal-title":"Cancer Gene Ther."},{"key":"BFsrep22850_CR19","doi-asserted-by":"publisher","first-page":"798467","DOI":"10.1155\/2010\/798467","volume":"2010","author":"JD Veltman","year":"2010","unstructured":"Veltman, J. D. et al. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol. 2010, 798467 (2010).","journal-title":"J Biomed Biotechnol."},{"key":"BFsrep22850_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12307-012-0100-4","volume":"5","author":"DJ Ireland","year":"2012","unstructured":"Ireland, D. J., Kissick, H. T. & Beilharz, M. W. The Role of Regulatory T Cells in Mesothelioma. Cancer Microenviron. 5, 165\u2013172 (2012).","journal-title":"Cancer Microenviron."},{"key":"BFsrep22850_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4161\/cbt.20557","volume":"13","author":"JD Predina","year":"2012","unstructured":"Predina, J. D. et al. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol Ther. 13, 745\u2013755 (2012).","journal-title":"Cancer Biol Ther."},{"key":"BFsrep22850_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12967-014-0245-7","volume":"12","author":"SA Fisher","year":"2014","unstructured":"Fisher, S. A. et al. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med. 12, 245 (2014).","journal-title":"J Transl Med."},{"key":"BFsrep22850_CR23","doi-asserted-by":"publisher","first-page":"e58132","DOI":"10.1371\/journal.pone.0058132","volume":"8","author":"V Relan","year":"2013","unstructured":"Relan, V. et al. Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One 8, e58132 (2013).","journal-title":"PLoS One"},{"key":"BFsrep22850_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1432-0436.1988.tb00806.x","volume":"37","author":"G Bepler","year":"1988","unstructured":"Bepler, G. et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37, 158\u2013171 (1988).","journal-title":"Differentiation"},{"key":"BFsrep22850_CR25","first-page":"527","volume":"13","author":"AM Orengo","year":"1999","unstructured":"Orengo, A. M. et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. 13, 527\u2013534 (1999).","journal-title":"Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis."},{"key":"BFsrep22850_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00418-004-0701-1","volume":"122","author":"MM Philippeaux","year":"2004","unstructured":"Philippeaux, M. M. et al. Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis. Histochem Cell Biol. 122, 249\u2013260 (2004).","journal-title":"Histochem Cell Biol."},{"key":"BFsrep22850_CR27","first-page":"197","volume":"28","author":"M Kobayashi","year":"2008","unstructured":"Kobayashi, M., Takeuchi, T. & Ohtsuki, Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res. 28, 197\u2013208 (2008).","journal-title":"Anticancer Res."},{"key":"BFsrep22850_CR28","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.2967\/jnumed.111.089177","volume":"52","author":"L Cottone","year":"2011","unstructured":"Cottone, L. et al. Evaluation of the role of tumor-associated macrophages in an experimental model of peritoneal carcinomatosis using (18)F-FDG PET. J Nucl Med. 52, 1770\u20131777 (2011).","journal-title":"J Nucl Med."},{"key":"BFsrep22850_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/modpathol.2011.144","volume":"25","author":"A Fassina","year":"2012","unstructured":"Fassina, A. et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 25, 86\u201399 (2012).","journal-title":"Mod Pathol."},{"key":"BFsrep22850_CR30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5858\/2008-132-397-AOITTD","volume":"132","author":"AM Marchevsky","year":"2008","unstructured":"Marchevsky, A. M. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 132, 397\u2013401 (2008).","journal-title":"Arch Pathol Lab Med."},{"key":"BFsrep22850_CR31","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","volume":"15","author":"F Vandermeers","year":"2009","unstructured":"Vandermeers, F. et al. Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma. Clin. Can. Res. 15, 2818\u20132828. (2009).","journal-title":"Clin. Can. Res."},{"key":"BFsrep22850_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldp047","volume":"93","author":"RM Rudd","year":"2010","unstructured":"Rudd, R. M. Malignant mesothelioma. Br Med Bull. 93, 105\u2013123 (2010).","journal-title":"Br Med Bull."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep22850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22850","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:11:33Z","timestamp":1672891893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep22850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3,29]]}},"alternative-id":["BFsrep22850"],"URL":"https:\/\/doi.org\/10.1038\/srep22850","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]},"assertion":[{"value":"2 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22850"}}